Literature DB >> 23122640

An animal model allowing controlled receptor expression for molecular ultrasound imaging.

Reshu Saini1, Anna G Sorace, Jason M Warram, Marshall J Mahoney, Kurt R Zinn, Kenneth Hoyt.   

Abstract

Reported in this study is an animal model system for evaluating targeted ultrasound (US) contrast agents binding using adenoviral (Ad) vectors to modulate cellular receptor expression. An Ad vector encoding an extracellular hemagglutinin (HA) epitope tag and a green fluorescent protein (GFP) reporter was used to regulate receptor expression. A low and high receptor density (in breast cancer tumor bearing mice) was achieved by varying the Ad dose with a low plaque forming unit (PFU) on day 1 and high PFU on day 2 of experimentation. Targeted US contrast agents, or microbubbles (MB), were created by conjugating either biotinylated anti-HA or IgG isotype control antibodies to the MB surface with biotin-streptavidin linkage. Targeted and control MBs were administered on both days of experimentation and contrast-enhanced US (CEUS) was performed on each mouse using MB flash destruction technique. Signal intensities from MBs retained within tumor vasculature were analyzed through a custom Matlab program. Results showed intratumoral enhancement attributable to targeted MB accumulation was significantly increased from the low Ad vector dosing and the high Ad vector dosing (p = 0.001). Control MBs showed no significant differences between day 1 and day 2 imaging (p = 0.96). Additionally, targeted MBs showed a 10.5-fold increase in intratumoral image intensity on day 1 and an 18.8-fold increase in image intensity on day 2 compared with their control MB counterparts.
Copyright © 2013. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23122640      PMCID: PMC3563100          DOI: 10.1016/j.ultrasmedbio.2012.08.016

Source DB:  PubMed          Journal:  Ultrasound Med Biol        ISSN: 0301-5629            Impact factor:   2.998


  22 in total

Review 1.  Ultrasound molecular imaging of atherosclerosis.

Authors:  Beat A Kaufmann
Journal:  Cardiovasc Res       Date:  2009-06-03       Impact factor: 10.787

2.  Dual targeting improves microbubble contrast agent adhesion to VCAM-1 and P-selectin under flow.

Authors:  E A Ferrante; J E Pickard; J Rychak; A Klibanov; K Ley
Journal:  J Control Release       Date:  2009-08-08       Impact factor: 9.776

3.  Molecular targeting of ultrasonographic contrast agent for detection of head and neck squamous cell carcinoma.

Authors:  Joseph A Knowles; Cara H Heath; Reshu Saini; Heidi Umphrey; Jason Warram; Kenneth Hoyt; Eben L Rosenthal
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2012-07

Review 4.  Molecular imaging: current status and emerging strategies.

Authors:  M A Pysz; S S Gambhir; J K Willmann
Journal:  Clin Radiol       Date:  2010-07       Impact factor: 2.350

5.  BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis.

Authors:  Sibylle Pochon; Isabelle Tardy; Philippe Bussat; Thierry Bettinger; Jean Brochot; Mathew von Wronski; Lisa Passantino; Michel Schneider
Journal:  Invest Radiol       Date:  2010-02       Impact factor: 6.016

6.  Gamma camera dual imaging with a somatostatin receptor and thymidine kinase after gene transfer with a bicistronic adenovirus in mice.

Authors:  Kurt R Zinn; Tandra R Chaudhuri; Victor N Krasnykh; Donald J Buchsbaum; Natalya Belousova; William E Grizzle; David T Curiel; Buck E Rogers
Journal:  Radiology       Date:  2002-05       Impact factor: 11.105

7.  Systemic delivery of a breast cancer-detecting adenovirus using targeted microbubbles.

Authors:  J M Warram; A G Sorace; R Saini; A V Borovjagin; K Hoyt; K R Zinn
Journal:  Cancer Gene Ther       Date:  2012-06-01       Impact factor: 5.987

8.  Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55).

Authors:  Marybeth A Pysz; Kira Foygel; Jarrett Rosenberg; Sanjiv S Gambhir; Michel Schneider; Jürgen K Willmann
Journal:  Radiology       Date:  2010-06-01       Impact factor: 11.105

9.  Ultrasonic imaging of tumor angiogenesis using contrast microbubbles targeted via the tumor-binding peptide arginine-arginine-leucine.

Authors:  Gregory E R Weller; Michael K K Wong; Ruth A Modzelewski; Erxiong Lu; Alexander L Klibanov; William R Wagner; Flordeliza S Villanueva
Journal:  Cancer Res       Date:  2005-01-15       Impact factor: 12.701

10.  Molecular imaging of the initial inflammatory response in atherosclerosis: implications for early detection of disease.

Authors:  Beat A Kaufmann; Chad L Carr; J Todd Belcik; Aris Xie; Qi Yue; Scott Chadderdon; Evan S Caplan; Jaspreet Khangura; Sherry Bullens; Stuart Bunting; Jonathan R Lindner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-10-15       Impact factor: 8.311

View more
  5 in total

1.  Molecular Ultrasound Imaging of Tissue Inflammation Using an Animal Model of Acute Kidney Injury.

Authors:  Kenneth Hoyt; Jason M Warram; Dezhi Wang; Sithira Ratnayaka; Amie Traylor; Anupam Agarwal
Journal:  Mol Imaging Biol       Date:  2015-12       Impact factor: 3.488

2.  Volumetric contrast-enhanced ultrasound imaging of renal perfusion.

Authors:  Marshall Mahoney; Anna Sorace; Jason Warram; Sharon Samuel; Kenneth Hoyt
Journal:  J Ultrasound Med       Date:  2014-08       Impact factor: 2.153

3.  Recent developments in dynamic contrast-enhanced ultrasound imaging of tumor angiogenesis.

Authors:  Reshu Saini; Kenneth Hoyt
Journal:  Imaging Med       Date:  2014-02-01

4.  The Impact of Surface Drug Distribution on the Acoustic Behavior of DOX-Loaded Microbubbles.

Authors:  Chia-Wei Lin; Ching-Hsiang Fan; Chih-Kuang Yeh
Journal:  Pharmaceutics       Date:  2021-12-04       Impact factor: 6.321

5.  Antitumor activity of integrin αVβ3 antibody conjugated-cationic microbubbles in liver cancer.

Authors:  Jiale Li; Ping Zhou; Hongbo Xu; Shuangming Tian; Wengang Liu; Yongfeng Zhao; Zheyu Hu
Journal:  Transl Cancer Res       Date:  2019-06       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.